ArticleOncoimmunology2012
The immuno-oncology framework: Enabling a new era of cancer therapy.
Article in Oncoimmunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- The Physiological and Therapeutic Role of CD47 in Macrophage Function and Cancer.Immunological investigations · 2025Review
- Just how transformative will AI/ML be for immuno-oncology?Journal for immunotherapy of cancer · 2024Review
- Dissecting the functions and regulatory mechanisms of disulfidoptosis-related RPN1 in pan-cancer: modulation of immune microenvironment and cellular senescence.Frontiers in immunology · 2024Article
- Nanomedicine-based cancer immunotherapy: a bibliometric analysis of research progress and prospects.Frontiers in immunology · 2024Review
- High expression of CDKN2A is associated with poor prognosis in colorectal cancer and may guide PD-1-mediated immunotherapy.BMC cancer · 2023Article
- Analysis of thymic generation of shared T-cell receptor α repertoire associated with recognition of tumor antigens shows no preference for neoantigens over wild-type antigens.Cancer medicine · 2023Article
- Cancer Immunoediting in the Era of Immuno-oncology.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Nanoparticle-Based Therapeutics to Overcome Obstacles in the Tumor Microenvironment of Hepatocellular Carcinoma.Nanomaterials (Basel, Switzerland) · 2022Review
- Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects.Cell death & disease · 2021Article
- Article
- The Role of Immunotherapy in the Treatment of Adrenocortical Carcinoma.Biomedicines · 2021Review
- Exploring the Health-Related Quality of Life of Patients Treated With Immune Checkpoint Inhibitors: Social Media Study.Journal of medical Internet research · 2020Article
- The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications.Cellular & molecular immunology · 2020Review
- Tumour Regression via Integrative Regulation of Neurological, Inflammatory, and Hypoxic Tumour Microenvironment.Biomolecules & therapeutics · 2020Review
- Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019Article
- Nanomaterials for modulating innate immune cells in cancer immunotherapy.Asian journal of pharmaceutical sciences · 2019Review
- Cancer Immunotherapy, Part 3: Challenges and Future Trends.P & T : a peer-reviewed journal for formulary management · 2017Article
- End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.Future oncology (London, England) · 2017Article
- The Safety of available immunotherapy for the treatment of glioblastoma.Expert opinion on drug safety · 2017Review
- Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations.Nature reviews. Drug discovery · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Developers of cancer immunotherapy have struggled for decades to achieve clinical success in using the patient's immune system to treat cancer. In the absence of a defined development paradigm for immunotherapies, conventional criteria established for chemotherapy were applied to these agents. This article summarizes the recent lessons for development of agents in the immunotherapy space, describes the systematic creation of a new clinical development paradigm for cancer immunotherapies and integrates this paradigm with the emerging methodological framework for a new clinical sub-specialty of immuno-oncology, which was driven by the collaborative work between the Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute in the US and the Association for Cancer Immunotherapy (CIMT) in Europe. This new framework provides a better defined development path and a foundation for more reproducible success of future therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.